MARKET

FMS

FMS

Fresenius Med Cr
NYSE
19.51
+0.11
+0.57%
Pre Market: 19.23 -0.28 -1.44% 05:05 06/25 EDT
OPEN
19.40
PREV CLOSE
19.40
HIGH
19.59
LOW
18.93
VOLUME
4.77K
TURNOVER
0
52 WEEK HIGH
27.72
52 WEEK LOW
15.90
MARKET CAP
11.45B
P/E (TTM)
10.97
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at FMS last week (0617-0621)?
Weekly Report · 23h ago
My Dividend Stock Portfolio: New May Dividend Record - 101 Holdings With 22 Buys
Stefan Redlich's dividend income hit an all-time high in May, up 13% Y/Y and 136% sequentially. In May, he added $149 to his yearly dividend income. His portfolio now has 101 Holdings with 22 Buys. Main portfolio picks included Ares Capital, Hercules Capital and Goldman Sachs BDC.
Seeking Alpha · 5d ago
FMS Makes Notable Cross Below Critical Moving Average
NASDAQ · 06/17 15:00
Weekly Report: what happened at FMS last week (0610-0614)?
Weekly Report · 06/17 09:10
Fresenius Medical Care takes next important step towards goal to reduce CO2 emissions in its operations
Fresenius Medical Care enters virtual power purchase agreements for renewable energy to clearly step forward in reducing CO2 emissions footprint Company enacts five virtual power agreements for around 580 gigawatt hours per year with wind and solar farms in Germany and the U.S. Energy farms scheduled to go into operation in 2024 and 2025 Important milestone for strategic sustainability goal to achieve climate-neutrality by 2040.
PR Newswire · 06/12 12:00
Weekly Report: what happened at FMS last week (0603-0607)?
Weekly Report · 06/10 09:11
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
NASDAQ · 06/07 15:02
FOCUS-AbbVie's tight grip on Humira market raises concerns about biosimilars
AbbVie's top-selling arthritis drug Humira has held onto more than 80% of patients in the U.S. Humira is the first top- selling drug to compete with a slew of biosimilars in the last year. Biosimilars are exact copies of branded drugs and are available at lower prices than Humira. Experts say there is little incentive for doctors to switch to cheaper alternatives.
Reuters · 06/07 10:00
More
About FMS
Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.

Webull offers Fresenius Medical Care AG stock information, including NYSE: FMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FMS stock methods without spending real money on the virtual paper trading platform.